Last 29 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.03 | 1.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.89 | 1.11 | 54.54 | 70.29 | 30.96 | 24.89 | 5.06 | 17.49 | 32.63 | 36.42 | 20.31 | 10.22 | 5.61 | 6.26 | 4.48 | 10.04 | 24.63 | 18.54 | 9.91 | 18.78 | 43.40 |
| — | -95.5% | +977.9% | +301.9% | -5.1% | -31.7% | -75.1% | +71.1% | +481.8% | +482.0% | +353.9% | +1.8% | -77.2% | -66.2% | -54.8% | -46.5% | -43.2% | -46.8% | -77.0% | -72.7% | -29.6% | |
| P/B Ratio | 2.46 | 3.09 | 4.90 | 3.66 | 3.12 | 2.11 | 1.99 | 2.68 | 3.29 | 4.87 | 2.65 | 4.02 | 1.70 | 1.98 | 2.11 | 1.86 | 2.20 | 2.34 | 1.70 | 2.36 | 3.75 |
| — | +46.4% | +146.0% | +36.2% | -5.1% | -56.6% | -24.8% | -33.2% | +94.0% | +146.1% | +25.5% | +116.1% | -22.9% | -15.4% | +24.4% | -21.3% | -41.3% | -38.6% | -44.7% | -53.8% | -34.0% | |
| P/FCF | 3.59 | 1.22 | — | — | — | — | — | — | — | — | — | — | 3.53 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.73 | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 99.7% | 57.4% | -1245.8% | 65.9% | 36.7% | -77.3% | -277.5% | -406.1% | -340.7% | -304.6% | -201.5% | -227.9% | -159.1% | -49.2% | -261.2% | -579.7% | -342.6% | -315.4% | -348.4% | -393.9% |
| — | +171.9% | +174.3% | -348.9% | +116.2% | +110.8% | +74.6% | -37.7% | -78.1% | -114.1% | -519.3% | +22.8% | +60.7% | +53.5% | +84.4% | +25.0% | -47.2% | -70.1% | -18.3% | +3.0% | -91.6% | |
| Operating Margin | -340.2% | 83.1% | -1041.7% | -1479.4% | -612.0% | -1157.7% | -109.7% | -340.7% | -486.7% | -433.8% | -401.4% | -272.7% | -299.1% | -216.7% | -87.3% | -338.6% | -717.8% | -432.9% | -399.9% | -444.3% | -513.2% |
| — | +107.2% | -849.8% | -334.3% | -25.7% | -166.8% | +72.7% | -24.9% | -62.8% | -100.2% | -360.1% | +19.5% | +58.3% | +50.0% | +78.2% | +23.8% | -39.9% | -53.1% | -7.4% | +9.2% | -71.6% | |
| Net Margin | -314.9% | 81.7% | -990.1% | -1394.3% | -576.1% | -1094.8% | -98.7% | -305.4% | -440.7% | -388.9% | -368.4% | -250.3% | -276.8% | -200.3% | -79.1% | -321.1% | -688.7% | -423.6% | -397.1% | -442.1% | -509.8% |
| — | +107.5% | -903.6% | -356.6% | -30.7% | -181.5% | +73.2% | -22.0% | -59.2% | -94.2% | -365.5% | +22.0% | +59.8% | +52.7% | +80.1% | +27.4% | -35.1% | -50.6% | -6.7% | +8.7% | -71.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.6% | 80.2% | -20.3% | -17.1% | -17.2% | -21.1% | -9.4% | -11.2% | -13.0% | -13.1% | -16.5% | -22.5% | -19.3% | -15.0% | -9.1% | -14.1% | -14.5% | -15.0% | -15.9% | -13.1% | -10.5% |
| — | +480.5% | -116.5% | -52.9% | -32.6% | -61.0% | +43.3% | +50.3% | +32.9% | +12.6% | -81.6% | -59.5% | -33.6% | +0.2% | +42.7% | -7.4% | -37.6% | -101.2% | -100.8% | -51.5% | -57.8% | |
| ROA | -39.0% | 63.5% | -15.3% | -13.2% | -12.9% | -15.5% | -7.2% | -8.8% | -9.9% | -9.6% | -10.8% | -12.4% | -12.6% | -11.2% | -6.7% | -10.4% | -10.7% | -10.7% | -10.9% | -9.3% | -7.8% |
| — | +509.5% | -112.1% | -50.0% | -30.5% | -62.4% | +33.4% | +29.4% | +21.7% | +14.9% | -60.6% | -20.0% | -18.5% | -4.8% | +38.3% | -11.3% | -37.2% | -87.8% | -89.2% | -51.9% | -57.8% | |
| ROIC | -54.0% | 118.8% | -16.4% | -17.0% | -17.9% | -17.9% | -8.6% | -10.8% | -12.9% | -13.9% | -16.9% | -20.9% | -18.1% | -14.6% | -8.7% | -12.8% | -13.1% | -12.8% | -14.2% | -12.4% | -11.3% |
| — | +763.4% | -91.7% | -58.1% | -38.2% | -28.5% | +49.4% | +48.5% | +28.5% | +4.8% | -94.3% | -62.9% | -38.5% | -14.5% | +38.8% | -3.6% | -15.3% | -28.7% | -26.9% | -5.9% | +19.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.07 | 0.14 | 0.12 | 0.10 | 0.15 | 0.12 | 0.06 | 0.05 | 0.07 | 0.08 | 0.17 | 0.15 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.04 |
| — | -55.5% | +24.5% | +120.3% | +92.6% | +110.7% | +49.2% | -68.0% | -64.8% | +110.4% | +116.3% | +344.1% | +287.6% | -11.4% | -33.9% | -24.5% | +3.4% | — | — | — | — | |
| Debt / EBITDA | — | 0.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.02 | 8.44 | 6.34 | 6.01 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 | 4.36 | 4.01 | 4.44 | 4.51 | 5.26 | 4.22 | 4.25 | 4.70 |
| — | +57.8% | -7.0% | -4.0% | +8.6% | +1.2% | +22.3% | +118.7% | +90.2% | +21.3% | +38.9% | -35.6% | -24.6% | -17.1% | -4.9% | +4.7% | -4.0% | -25.7% | -50.1% | -34.4% | -29.9% | |
| Quick Ratio | 7.02 | 8.44 | 6.34 | 6.01 | 7.02 | 5.35 | 6.82 | 6.26 | 6.46 | 5.28 | 5.57 | 2.86 | 3.40 | 4.36 | 4.03 | 4.46 | 4.52 | 5.26 | 4.23 | 4.25 | 4.70 |
| — | +57.8% | -7.0% | -4.0% | +8.6% | +1.2% | +22.3% | +118.7% | +90.2% | +21.3% | +38.4% | -35.8% | -24.9% | -17.1% | -4.8% | +5.1% | -3.7% | -25.7% | -50.0% | -34.4% | -29.9% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NRIX stock.
Nurix Therapeutics, Inc.'s current P/E is 6.0x. The average P/E over the last 1 quarters is 1.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nurix Therapeutics, Inc.'s current operating margin is -340.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nurix Therapeutics, Inc.'s business trajectory between earnings reports.